Statin OTC Switch Debate Reflects Poorly On Physicians - FDA's Woodcock
Executive Summary
The discussion of switching cholesterol agents to over-the-counter status may reflect the failure of physicians to provide adequate counseling to patients, FDA Center for Drug Evaluation & Research Director Janet Woodcock, MD, told the agency's OTC switch public hearing June 29.
You may also be interested in...
FDA OTC Switch Policy: Key Issue Is Crafting Labeling From Public Domain
FDA is considering holding a public meeting to discuss Rx-to-OTC switch issues to clarify the agency's current thinking on which prescription categories have the potential to move over-the-counter in the near future
FDA OTC Switch Policy: Key Issue Is Crafting Labeling From Public Domain
FDA is considering holding a public meeting to discuss Rx-to-OTC switch issues to clarify the agency's current thinking on which prescription categories have the potential to move over-the-counter in the near future
Gynetics Exec Supports Restricted Access For OTC Emergency Contraceptives
Emergency contraceptive maker Gynetics would support age requirements and other restrictions on over-the-counter access to emergency contraception products, Gynetics Chief Financial and Operating Officer Jack Stover suggested to an FDA Rx-to-OTC switch public meeting June 29.